The paper “Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas” published in the European Journal of Cancer is undoubtedly of significance. Curious about the findings, I interviewed Professor Dr. Lars Lindner of Ludwig-Maximilians-Universität (LMU) in Munich. The renowned expert kindly agreed to respond to my questions regarding the various modalities compared in the paper, including CT, regional hyperthermia and immunotherapeutic agents, as well as the implications for the future. We have also produced an infographic that illustrates the long-term results of the EORTC 62961-ESHO 95 trial published in JAMA Oncology (Issels et al., 2018).Summary, Interview, Infographic
- 13th ICHO (International Congress of Hyperthermic Oncology) Rotterdam, Netherlands (virtual) Oct. 06 – 09, 2021
- ÖGRO Jahrestagung 2021 (Austrian Society for Radiation Oncology) Vienna, Austria Oct. 07 – 09, 2021
- Sarkomkonferenz Berlin, Germany Nov. 18 – 20, 2021
(hybrid) Nov. 19 – 20, 2021
BrochuresView All Brochures
On June 17, Tübingen University Hospital officially inaugurated its new MRT hyperthermia system, supplied by Dr. Sennewald Medizintechnik GmbH/
The photo above shows those taking part in the celebrations: (left to right, Copyright Universitätsklinikum Tübingen/Janina Fischer) Prof. Dr. Daniel Zips (Director of the University Department of Radiation Oncology), Susanne Schäfer (MTA in radiology), Prof. Dr. Michael Bamberg (Chief Medical Director and Chairman of the Executive Board), Dr. Gerhard Sennewald (CEO), Prof. Dr. Konstantin Nikolaou (Director of the University Department of Radiology and of Diagnostic and Interventional Radiology), Prof. Dr. Jürgen Schäfer (Head of Pediatric Radiology), and Thomas Richter of Philips GmbH.
The state-of-the-art system will be shared by the Clinic for Radiation Oncology and the Department of Diagnostic and Interventional Radiology. In this way, it not only serves cancer treatment but will also be used for diagnostic imaging, primarily for pediatric radiology. Following the opening ceremony, members of the clinic demonstrated the unit, explaining the various treatment options, and answered questions from members of the press.
Paul Turner, CTO at Pyrexar Medical Corporation covers “Present and Future Hyperthermia Technology Evolution”.
Paul Turner has been developing hyperthermia and ablation heat treatment methods for more than 40 years, including RF phased array systems for deep non-invasive and invasive phased arrays.